← Dyne Therapeutics, Inc. (DYN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Dyne Therapeutics, Inc. (DYN)
Pharmaceutical Preparations · market cap $3.1B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Dyne Therapeutics (DYN) is a ~$3.4B market-cap rare neuromuscular disease biotech with two late-stage programs: zeleciment basivarsen (DYNE-101) in Phase 3 for Myotonic Dystrophy Type 1 (DM1) and Zeleciment Rostudirsen (DYNE-251) in Phase 3 for Duchenne Muscular Dystrophy (DMD). The company holds $753M in cash against a 15.6-month runway, with R&D spend accelerating sharply to $398M in 2025 as both Phase 3 programs advance.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DYNE-101 | Phase 2 | Myotonic Dystrophy Type 1 (DM1) |
| zeleciment basivarsen (DYNE-101) | Phase 3 | Myotonic Dystrophy Type 1 (DM1) |
| DYNE-251 | Phase 2 | Duchenne Muscular Dystrophy (DMD) |
| Zeleciment Rostudirsen (DYNE-251) | Phase 3 | Duchenne Muscular Dystrophy (DMD) |
Price & technical context
3-month
-31.4%
6-month
-12.6%
12-month
+25.1%
52-wk range
$12.50–$26.78
vs 50-day MA
-30.3%
vs 200-day MA
-19.4%
Realized vol
75.3%
Max drawdown
-81.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DYN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.